Since the presence of microvascular invasion or the grade of differentiation is not available pre-operatively as standard when clinical decisions about prioritisation and listing need to be made, models using biomarkers, such as AFP and NLR, together with the diameter and number of HCC nodules, have been developed. This evidence concerns the gene AFP and hepatocellular carcinoma.